Equillium Advances EQ504 into Phase 1 Trials with $57M Cash Runway
Event summary
- Equillium expects to initiate Phase 1 proof-of-mechanism study for EQ504 in Q4 2026 with topline data anticipated six months later.
- Cash and cash equivalents totaled $57.2M as of June 30, 2026, expected to fund operations into 2029.
- R&D expenses for Q2 2026 were $2.8M, down from $4.1M in the same period in 2025.
- Equillium initiated IND-enabling development activities for EQ302, an oral bi-specific inhibitor of IL-15 and IL-21 for celiac disease.
The big picture
Equillium's progress with EQ504 reflects the broader trend in biotech toward targeted therapies for autoimmune and inflammatory disorders. The company's ability to extend its cash runway into 2029 positions it favorably amidst competitive pressures in the inflammation and immunology space. The establishment of a Clinical Advisory Board underscores the strategic importance of leveraging external expertise to guide clinical development.
What we're watching
- Clinical Progress
- The pace at which EQ504 advances through Phase 1 trials will determine the timeline for potential efficacy studies in ulcerative colitis.
- Financial Sustainability
- Whether Equillium's $57.2M cash runway is sufficient to support operations into 2029, given current R&D and G&A expenses.
- Pipeline Expansion
- How the development of EQ302 for celiac disease impacts Equillium's strategic focus and resource allocation.
Related topics